| Literature DB >> 12430929 |
Wolf K Hofmann1, H Phillip Koeffler.
Abstract
Myelodysplastic syndromes (MDS) are characterized by peripheral cytopenias in combination with a hyperplastic bone marrow. During the last 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndromes. The classification according to the World Health Organization (WHO) includes mainly morphological criteria and is supplemented by the International Prognostic Scoring System (IPSS) which takes cytogenetical changes into consideration when determining the prognosis of MDS. Also MDS after radiotherapy, chemotherapy or chemical exposure must be distinguished from primary MDS. The underlying mechanisms in primary MDS have not yet been established but it is a multistep alteration to the hematopoietic stem cells that include genes involved in cell cycle control, mitotic checkpoints as well as growth factor receptors, secondary signal proteins and transcription factors which gives the cell a growth advantage over its normal counterpart.Entities:
Mesh:
Year: 2002 PMID: 12430929 DOI: 10.1007/bf03165121
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490